Public Consultation on two Ph. Eur. Chapters on Pharmaceutical Technology Procedures

Recommendation
13-15 May 2025
Vienna, Austria
Practical Approaches for USP General Chapter <1058> Compliance in the QC Laboratory
The European Directorate for the Quality of Medicines & HealthCare (EDQM) indicated in a press release dated 01 February 2023 that the public consultation on two Ph. Eur. chapters on pharmaceutical technology procedures has been started. These are the revised general chapter 2.9.3 "Dissolution of tablets and capsules" and the new chapter 2.9.55 "Characterisation of powder behaviour during compression". Both texts were recently published in Pharmeuropa 35.1.
General Chapter 2.9.3. Dissolution of Tablets and Capsules
The aim of the revision was to improve comprehensibility and to harmonize the terminology used. In particular, the number of significant digits for pH and temperature has been adjusted. Further information on the changes made can also be found in a summary that we recently published.
New General Chapter 2.9.55. Characterisation of Powder Behaviour during Compression
The new chapter is divided into the following five main sections:
- 1. Introduction
- 2. Description of the powder compression phases
- 3. Compression equipment
- 4. Characterisation of the compaction behaviour
- 5. Conclusion and recommendations
In the introduction to the new chapter, it is pointed out that powder compression is a critical process in tablet manufacturing. Despite extensive experience, many problems, including capping, lamination, friability and sticking, are still encountered during the compression stages.
The complete texts and further details on the revision as well as the possibility to comment can be found on the Pharmeuropa Website after registration. The deadline for submitting comments is 31 March 2023 in both cases.
Related GMP News
07.05.2025Public Consultation on ICH M13B Guideline on Bioequivalence launched in Switzerland
07.05.2025BioPhorum publishes Guidance for ICH Q2(R2) and Q14 Implementation
23.04.2025OTC Drug Production Ceased after FDA Warning Letter
23.04.2025EMA publishes Draft of ICH M13B Guideline on Bioequivalence
16.04.2025EMA publishes four new product-specific Bioequivalence Guidance
09.04.2025Missing Tests and Altered Records: FDA Warns Chinese OTC Manufacturer